Bringing the fundamentals into focus…
Back to Nurix Therapeutics, Inc.
How Nurix Therapeutics, Inc. stacks up
NRIX · against 352 other Healthcare companies of similar size
Valuation
75/ 100
Above the middle of the pack.
Ranked #99 of 353 · scores higher than 72% of peers
Bars: peers in each 10-point band of the valuation score30 peers with a valuation score of 70–79, including NRIX · Click a bar to see the companies
Why valuation scores 75?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -15.4% vs peer median 4.0%
- lower earnings for the price paid: weaker than 83% of peers. Earnings yield: 10.5% vs peer median 1.5%
- less free cash flow for the price paid: weaker than 76% of peers. Free cash flow yield: 13.1% vs peer median 0.0%
Metric by metric
Position: dot = NRIX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NRIX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 344 reported | -13.4% | 2.3% | 10% | 30% | |
| EBITDA yieldHigher is better · 350 reported | -15.4% | 4.6% | 7% | 50% | |
| Free cash flow yieldHigher is better · 179 reported | -11.4% | -0.0% | 11% | 20% | |
| Book yieldHigher is better · 344 reported | 15.0% | 31.9% | 22% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around NRIXScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score